Centrix Pharmaceutical to launch Clofera

BIRMINGHAM, Ala. Centrix Pharmaceutical recently announced plans to commercially launch Clofera for the temporary relief of cough and nasal congestion.

Clofera contains a non-narcotic cough suppressant — chlophedianol hydrochloride — in addition to a nasal decongestant — pseudoephedrine hydrochloride — and is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever or other upper respiratory allergies.

The product will be merchandised behind the pharmacy counter as a pseudoephedrine product.

“We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects,” stated John Booth, president and CEO for Centrix. “Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further complements our goal to develop and expand the Centrix specialty portfolio.”